MARSEILLE, France I3, 2024 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S Food ...

The researchers concluded that oART, with BH technique, shows promise in reducing PTV margins and OAR doses in gastric ...

Oppenheimer Center for Neurobiology of Stress and Resilience, Clinical Studies and Database Core, Goodman-Luskin Microbiome ...

Unfortunately, too many insurers — including Medicare — still see obesity as a cosmetic issue instead of the disease that it ...

The following is a summary of "Preoperative Chemoradiotherapy for Resectable Gastric Cancer," published in the September 2024 ...

Support for the neurokinin-1 receptor (NK1R) antagonist included a negative phase III trial and a positive phase II study ...

Oral treatments are prone to faulty absorption due to the delayed gastric emptying blocking delivery or symptoms causing vomiting of pills, further complicating oral drug therapy. Those suffering from ...

Clearly frustrated by the U.S. FDA’s rejection of tradipitant to treat gastroparesis, Vanda Pharmaceuticals Inc. CEO Mihael Polymeropoulos said the agency is discouraging drug development for the ...

Gastric cancer, or stomach cancer, is a type of cancer that begins in the mucus-producing cells on the inside lining of the stomach. The most common type of stomach cancer is adenocarcinoma.

Get the best offers for your Daily Journal subscription using these great specials. If you want to see other subscription ...

I-Mab (IMAB) said that an expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody ...

The Stormont Vail Health Weight Management program completed its 500th bariatric surgery since its launch in 2018.